目的:观察自体DC-CIK细胞联合经皮微波热凝(percutaneous microwave coagulation therapy,PMCT)治疗肝癌的临床疗效。方法:收集2012年1月至2014年2月东方肝胆外科医院生物治疗科收治的44例行PMCT+DC-CIK治疗的肝癌患者(联合治疗组),先行血细胞分离单采并进行DC-CIK细胞培养,采血后第2天进行PMCT治疗;培养10 d后行CIK细胞回输及DC疫苗皮内注射。此后分别于1、2个月后行第2疗程及第3疗程DC-CIK细胞治疗。同时选取44例单纯行PMCT治疗的同期肝癌患者与之配对(对照组),该组患者仅行PMCT治疗。观察两组治疗前后的AFP变化、免疫功能、无进展生存期、总生存期及不良反应。结果:联合治疗组、对照组治疗后均有AFP下降及外周血调节性T细胞降低,但联合治疗组下降程度更显著(P<0.05);对照组治疗后外周血淋巴细胞亚群无明显变化(P>0.05),而联合治疗组则显著升高(P<0.05)。联合治疗组中位无进展生存时间及中位总生存时间均较对照组延长(7.1 vs 4.9个月;21.5 vs 14.0个月,均P<0.05)。结论:自体DC-CIK细胞联合PMCT是治疗肝癌的一种有效方法,可提高患者免疫功能、延缓肿瘤复发、延长生存期,且不良反应较少。 Objective: To observe the clinical efficacy of autologous DC-CIK cells combined with percutaneous microwave coagulation therapy (PMCT) in the treatment of liver cancer. Methods: Forty-four patients with hepatocellular carcinoma (PMCT + DC-CIK) treated with PMCT + DC-CIK were enrolled in the Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital between January 2012 and February 2014. The primary hematopoietic stem cells were collected and DC-CIK cells PMCT treatment was performed on the second day after blood collection. CIK cells were transfused and the DC vaccine was injected intradermally after 10 days of culture. After 1, 2 months after the first two courses and the third course of DC-CIK cell therapy. Forty-four patients with hepatocellular carcinoma treated with PMCT alone were matched (control group), and only PMCT was used in this group. AFP changes before and after treatment, immune function, progression-free survival, overall survival and adverse reactions were observed. Results: The decrease of AFP and the decrease of T regulatory cells in the combination group were found in the combination therapy group and the control group (P <0.05), but there was no significant change in the peripheral blood lymphocyte subsets in the control group (P> 0.05), but the combination therapy group was significantly higher (P <0.05). The median progression-free survival and median overall survival were longer in the combined treatment group than in the control group (7.1 vs. 4.9 months; 21.5 vs. 14.0 months, all P <0.05). Conclusion: The combination of autologous DC-CIK cells and PMCT is an effective method for the treatment of hepatocellular carcinoma, which can improve immune function, delay tumor recurrence and prolong survival, with fewer adverse reactions.